Entries by Rebecca.Mercer@cancercare.on.ca

FDA’s RWE Framework

Earlier in December the FDA released a new framework outlining how they will use Real World Evidence (RWE) and Real World Data (RWD) in decision making for new drugs and biologics.  Under the new framework, the FDA will use the following three criteria to evaluate RWE/RWD: 1. Whether the RWD are fit (more…)

ARCC 2019 Abstract Submission NOW OPEN!

We are pleased to announce that abstract submission for the 2018 ARCC Conference is NOW OPEN! We encourage you to submit your work and join us in Halifax, May 27-28, 2019. Registration will open in mid-January 2019. Visit our conference webpage at  https://cc-arcc.ca/arcc-conference-2019/ for the most up-to-date conference information including (more…)